Company: CNTB
Filing Date: 2025-06-10
Form Type: F-3
Source: 0001193125-25-138482
Chunk: 11

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-06-10
Form: F-3
Chunk 11
---
 in the documents that are incorporated by reference into this prospectus. Risks Related to Our Limited Operating History, Financial Position and Capital Requirements

| • |     | We have a limited operating history, have incurred significant operating losses since our inception and expect                                                                                 
 to incur significant losses for the foreseeable future. We might never generate any additional revenue or become profitable or, if we achieve profitability, we might be unable to sustain it. |

| • |     | We will require substantial additional capital to achieve our goals, and a failure to obtain or access this                                                                                                                                              
 necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. Our existing capital will not be sufficient for us to 
 fund rademikibart (formerly CBP-201) or any other future product candidates (collectively, our “Product Candidates”) through regulatory approvals, and we will need additional capital to complete                                                       
 their development and commercialization.                                                                                                                                                                                                                 |

| • |     | Raising additional capital may cause substantial dilution to our shareholders, including holders of our ADSs, 
 restrict our operations or require us to relinquish rights to our technologies or Product Candidates.         |

Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates

| • |     | Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur                                                
 unforeseen costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our Product Candidates. |

| • |     | We depend on enrollment of patients in our clinical trials for our Product Candidates. If we experience delays                                                                                       
 or difficulties enrolling patients in our clinical trials, our research and development efforts and business, financial condition, and results of operations could be materially adversely affected. |

6

| • |     | Our Product Candidates may be associated with serious adverse events or undesirable side effects or have other                                                                               
 properties that could delay or halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. |

| • |     | We have conducted and may continue to conduct clinical trials for our Product Candidates in international      
 sites, and the applicable regulatory authority may not accept data from trials conducted in foreign locations. |

| • |     | Interim, “top-line” or preliminary data from our clinical                                                                                                                                                           
 trials that we announce or publish from time to time may change as more patient data